Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Treating EGFR Exon 20 Insertion+ mNSCLC: Equipping Oncology Nurses to Optimize Care
  • CE

Credits Available
Registered Nurses: 1.5 Nursing contact hours
Released: June 3, 2022 Expiration: June 2, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Takeda Pharmaceuticals U.S.A., Inc.
Marianne Davies, DNP, CNS, ACNP-BC, AOCNP
Matthew Gubens, MD, MS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the significance of EGFR exon 20 insertions with appropriate patients with lung cancer
  • Evaluate the clinical data of new and emerging agents targeting EGFR exon 20 insertion mutations
  • Describe the biology and pathology of the EGFR-targeting toxicity profile
  • Develop care plans for monitoring and managing agent-specific adverse events for the treatment of patients with EGFR exon 20 insertion NSCLC receiving these new therapies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP

Associate Professor
Coordinator of Oncology Concentration

Yale University School of Nursing
Oncology Nurse Practitioner
Medical Oncology
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP, has no relevant conflicts of interest to report.
Matthew Gubens, MD, MS

Associate Professor
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Genzyme/Sanofi, iTeos, and Surface and funds for research support paid to his institution from Amgen, Johnson & Johnson, Merck, Novartis, OncoMed, Roche, and Trizell.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Kelly Brandt, PharmD
Kelly Gaertner Brandt, PharmD, BCOP, BCPS, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Brian Purves
Brian Purves, PharmD, MBA, has disclosed that he has received salary from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for oncology nurses, nurse practitioners, and clinical nurse specialists who care for patients with lung cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of oncology nurses, nurse practitioners, and clinical nurse specialists to understand and explain clinical data on recently approved therapies targeting EGFR exon 20 insertion mutations and the differences in monitoring and managing AEs for their patients with lung cancer receiving these therapies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education 

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 03, 2022, through June 02, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Treating EGFR Exon 20 Insertion+ mNSCLC: Equipping Oncology Nurses to Optimize Care
  • CE

Loading...
Watch this on-demand webcast of a live CCO webinar where an oncology nurse practitioner and a medical oncologist discuss management of EGFR exon 20 insertion–positive advanced non‑small-cell lung cancer, from biomarker testing to monitoring and management strategies for adverse events with new therapies targeting this alteration.
Marianne Davies, DNP, CNS, ACNP-BC, AOCNP
Matthew Gubens, MD, MS
Registered Nurses: 1.5 Nursing contact hours
Released: June 3, 2022 Expiration: June 2, 2023

Related Content

Experts highlight key studies being presented at the upcoming 2022 WCLC annual meeting in this commentary from Clinical Care Options (CCO)

Wade T. Iams, MD, MSCI Heather Wakelee, MD Released: August 5, 2022

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Downloadable slideset on the molecular determinants for the selection of optimal therapy for patients with NSCLC, from Clinical Care Options (CCO)

Matthew Gubens, MD, MS Craig Mackinnon, MD, PhD Released: July 29, 2022

Video featuring nursing perspective on biomarker testing in NSCLC and targeted therapy for actionable genomic alterations, from Clinical Care Options (CCO)

person default Beth Sandy, MSN, CRNP Elizabeth S. Waxman, BSN, MSN, ANP-BC Registered Nurses: 1.0 Nursing contact hour Released: July 27, 2022 Expired: July 26, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Takeda Pharmaceuticals U.S.A., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings